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Abstract: Membrane-associated guanylate kinase (MAGUK) with inverted domain structure-1
(MAGI1) is an intracellular adaptor protein that stabilizes epithelial junctions consistent with a tumor
suppressive function in several cancers of epithelial origin. Here we report, based on experimental
results and human breast cancer (BC) patients’ gene expression data, that MAGI1 is highly expressed
and acts as tumor suppressor in estrogen receptor (ER)+/HER2− but not in HER2+ or triple negative
breast cancer (TNBC). Within the ER+/HER2− subset, high MAGI1 expression associates with
ESR1 and luminal genes GATA3 and FOXA1 expression and better prognosis, while low MAGI1
levels correlates with higher histological grade, more aggressive phenotype and worse prognosis.
Experimentally, MAGI1 downregulation in the ER+ human BC cells MCF7 impairs ER expression
and signaling, promotes cell proliferation, and reduces apoptosis and epithelial differentiation.
MAGI1 downregulation in the ER+ murine BC cell line 67NR accelerates primary tumor growth and
enhances experimental lung metastasis formation. MAGI1 expression is upregulated by estrogen/ER,
downregulated by prostaglandin E2/COX-2axis, and negatively correlates with inflammation in
ER+/HER2− BC patients. Taken together, we show that MAGI1 is a new potential tumor suppressor in
ER+/HER2− breast cancer with possible prognostic value for the identification of patients at high-risk
of relapse within this subset.
Keywords: breast cancer; MAGI1; prognosis; stratification; estrogen receptor; recurrence;
inflammation; COX-2; metastasis
1. Introduction
MAGI1 is a cytoplasmic scaffolding protein present at cell-to-cell contacts [1–3]. MAGI1 expression
is downregulated during cancer progression and was proposed to act as a tumor suppressor in several
cancers, including hepatocellular carcinoma, colorectal, cervical and gastric cancers [4–7]. We have
previously shown that silencing MAGI1 expression in colorectal cancer (CRC) cells promotes primary
tumor growth and metastasis associated with loss of E-cadherin at cell contacts and Wnt signaling
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activation, while MAGI1 overexpression had opposite effects. We therefore proposed that MAGI1
is a tumor suppressor in CRC [4]. Furthermore, MAGI1 interacts with the tumor suppressor PTEN
leading to PTEN and E-cadherin stability at cell–cell contacts [8–11]. Stimulated by these observations
we sought to analyze whether MAGI1 may also act as a tumor suppressor in breast cancer.
Breast cancer (BC) is a heterogeneous disease that differs at the genetic, histopathological
and clinical levels [12]. Three clinically relevant biological BC subtypes have been defined:
Estrogen/Progesterone Receptor positive (ER+/PR+), Human Epidermal growth factor Receptor
2 amplified (HER2+) and triple negative (TNBC; i.e., ER−/PR-/HER2−) BC [13]. The introduction of
anti-estrogen (e.g., tamoxifen) and anti-HER2 (e.g., Herceptin)-based adjuvant treatments for ER+ and
HER2+ BC, respectively, in combination with mastectomy or breast-saving surgery, have improved
survival by about 30% in the past three decades [14]. For TNBC there are still no specific established
therapies due to lack of defined targets, and radio- and chemotherapies are commonly used instead [15].
Additional potential therapeutic targets for personalized therapies have been identified (e.g., PI3KCA,
EGFR, PARP, and PDL/PDL-1) [16–18]. Gene expression profiling classified BC into different molecular
subtypes with distinct features and clinical outcomes: luminal A, luminal B, HER2-enriched, basal-like,
claudin-low and normal-like subtypes [19–22]. This molecular classification contributed to refine the
diagnosis and selection of the most appropriate therapy. For instance, among the estrogen/progesterone
receptor positive (ER+/PR+) tumors expressing luminal epithelial genes and ER target genes, a large
subset has low proliferation, responds well to anti-estrogen (hormonal) therapy with ER antagonists,
such as tamoxifen or fulvestrant, and has a favorable outcome [23]. This subset is also referred
to as luminal A. However, some ER+ breast cancers have a higher risk for recurrence and poorer
prognosis, especially in younger women and benefit more from adjuvant chemotherapy [24–26].
In these patients, tumors are of higher grade, more proliferative, and have a higher risk of metastatic
progression [24–27]. These highly proliferative ER+ breast cancers are referred to as luminal B [19–22].
These tumors have lower expression of luminal and ER target genes, indicating that they may rely
upon alternative pathways for growth (e.g., EGFR/HER2/MAPK or PI3K/AKT) [28,29]. In consequence,
highly proliferative ER+ BC at high risk of recurrence may benefit more from a combined therapeutic
strategy including adjuvant chemo- and hormonal therapies [25,26,30]. In this context, tests based
on gene-expression in the primary tumor, have shown clinical potential in identifying patients with
early BC with an excellent prognosis who could be spared of adjuvant chemotherapy [24–26,31–33].
It remains nevertheless of critical importance to identify molecular drivers of progression in ER+/HER2−
BC to further refine therapeutic approach in the high-risk subset of ER+/HER2− BC patients.
Here, using a combined experimental and clinical approach, we report the identification of MAGI1
as tumor suppressor in ER+/HER2− BC with possible prognostic value for the identification of patients
at high-risk of relapse within this subset.
2. Results
2.1. MAGI1 Is Highly Expressed in ER+ Breast Cancer
MAGI1 expression was shown to be downregulated in several cancers, including hepatocellular
carcinoma, colorectal, cervical, and gastric cancers [4–7], but little is known about its expression in
BC and its subtypes. To address this question, we analyzed METABRIC and TCGA gene expression
data sets [34,35] of primary human breast cancers and observed that MAGI1 expression is higher
in ER+/HER2− compared to HER2+ and ER−/HER2− BC subtypes (Figure 1a). Consistent with this
observation, MAGI1 expression positively correlates with ESR1 (the gene coding for ER) and luminal
fate transcription factors GATA3 and FOXA1 expression within ER+/HER2− breast cancers in both
data sets (Figure 1b, significant correlations are in blue, anti-correlations are in red). A similar positive
correlation between MAGI1, ESR1, and GATA3 expression is also found in tumor samples derived
from the MMTV-PyMT spontaneous model of BC (Figure 1c). Additionally, and consistently, MAGI1
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protein is highly expressed in the ER+ human cell line MCF7 compared to HER2+ BT-474 cell line and
the basal like/TNBC-derived MDA-MB-231 cell line (Figure 1d).
These results indicate that in BC, MAGI1 expression is higher in the ER+ subtype and positively
correlated with the expression of ESR1 and the luminal genes GATA3 and FOXA1.
Figure 1. Membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1) expression
correlates with estrogen receptor breast cancer (ER+ BC) subtype. (a) MAGI1 expression from
METABRIC and TCGA microarray analysis by BC subtype ER−/HER2−, ER+/HER2−, and HER2+.
Statistical analysis was performed by Kruskal–Wallis test (non-parametric one-way ANOVA). (b) Heat
plot correlation matrices in ER+HER2− patients from METABRIC and TCGA data. Significant
correlations are in blue, anti-correlations are in red. (c) MAGI1 mRNA levels positively correlates with
ESR1 and GATA3 expression in MMTV-PyMT tumor samples. The data from qPCR are shown as
a percentage of Arbp1. Correlation analysis was calculated with Pearson’s R correlation test (n = 12
tumors). (d) Western blot showing MAGI1 and ERα protein levels in MCF7 (ER+/HER2−), BT474
(HER2+), and MDA-MB-231 (basal-like, ER−/HER2−) cell lines. GAPDH is used as loading control.
Band intensity ratio adjusted to GAPDH is shown next to the blot.
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2.2. MAGI1 Is Upregulated by Estrogen Receptor Alpha (erα) and Contributes to ER Signaling
To investigate whether MAGI1 may be regulated by estrogen and ERα, we first analyzed
bioinformatically the MAGI1 promoter sequence and noticed that it contains five different putative
estrogen response elements (EREs) half-sites at positions −1009/−1013 (Site I), −1212/−1216 (Site II),
−1736/−1740 (Site III); −1843/−1847 (Site IV) and −1862/−1866 (Site V) (Figure 2a). To functionally test
whether MAGI1 mRNA expression is indeed regulated by estrogen, MCF7 cells were serum-starved
for 48 h and subsequently treated for 6 h with 10−6 M 17β-estradiol (E2) or vehicle only. As shown in
Figure 2b, MAGI1 mRNA levels were up-regulated upon E2 treatment together with progesterone
receptor (PGR) and BRCA1, two known estrogen regulated genes [36]. ESR1 expression, which is
known to be negatively regulated by E2 itself [37], showed a trend toward reduced expression but the
difference was not significant. Next, we tested whether MAGI1 itself functionally contributed to E2/ER
signaling. MAGI1 downregulation in MCF7 cells prevented induction of PGR and BRCA1 expression
in response to E2 stimulation (Figure 2c). MAGI1 downregulation in MCF7 cells decreased ESR1
mRNA and ERα protein levels (Figure 2d). To gather additional evidence that these effects were E2/ER
specific, we stimulated MCF7 control cells (NSControl) and MCF7 cells with downregulated MAGI1
(sh4MAGI1), with E2 in the presence of the ER antagonist tamoxifen and ICI 182,780, and measured
expression of MAGI1, ESR1 and PGR by RT-qPCR. Results show that tamoxifen and ICI 182,780 blunted
the effects of E2 stimulation on MAGI1, ESR1 and PGR expression (Figure 2e,f). Taken together these
data suggests the involvement of MAGI1 on ER signaling.
To complement experimental results, we performed a gene ontology (GO) analysis for biological
processes on the above-mentioned human data sets, focusing only on ER+/HER2− BC. This analysis
revealed that MAGI1 expression positively correlates with biological processes consistent with
increased ER activity such as transcription from RNA polymerase II (GO:0006357, q = 1.41 × 10−13),
gene expression, RNA metabolism, macromolecule biosynthesis, transport and localization and histone
modifications (Figure S1a, Table S1).
Taken together these results indicate that MAGI1 is regulated by E2/ERα and at the same time is
required for expression of ERα and ERα-dependent genes in ER+ BC cells.
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Figure 2. MAGI1 is upregulated by estrogen receptor (ER) α and MAGI1 contributes to ER signaling
(a). Schematic representation of estrogen response element (ERE) half-site motifs in MAGI1 promoter
sequence. The adenine (a) of the first codon, atg, is numbered as 1. The sequences of ERE sites I-V
core regions are underlined and highlighted in bold. (b,c) Real time PCR quantification of (b) ESR1,
MAGI1, PGR, and BRCA1 mRNA in MCF7 NSControl and (c) MCF7 sh4MAGI1 upon 17β-estradiol
(E2) treatment (n = 3 independent experiments, each analyzed in triplicate) (d). Western blot and
qPCR showing MAGI1 and ERα protein and mRNA levels, respectively, in MCF7 NSControl and
MCF7 sh4MAGI1 cells. GAPDH is used as loading control. Band intensity ratio adjusted to GAPDH
is shown next to the blot. (e,f) Real time PCR quantification of ESR1, MAGI1 and PGR mRNA in (e)
MCF7 NSControl and (f) MCF7 sh4MAGI1 upon 17β-estradiol (E2) treatment alone or in the presence
of tamoxifen or ICI 182,780 (or vehicle only, control) as indicated (n = 3 independent experiments,
each analyzed in triplicate). qPCR data are shown as percentage of the value of the housekeeping
gene GAPDH, and represent mean values ± S.D. Statistical analysis was performed by unpaired t-test.
ns = no statistical difference, * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001.
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2.3. MAGI1 Downregulation Increases Proliferation, Reduces Apoptosis and Activates PI3K/Wnt Signaling in
MCF7 Cells
ER is a mitogenic pathway for normal breast epithelial cells and ER+ BC cells, however, loss of
ER expression/function is associated with increased proliferation and aggressiveness [38]. To test
whether MAGI1 modulation may affect cell growth, we monitored cell proliferation, cell cycle
progression, survival, and apoptosis in MCF7 cells with silenced MAGI1 compared to non-silenced (NS)
control MCF7 cells. MAGI1 silencing (sh4MAGI1) increased MCF7 growth and survival compared to
non-silenced (NSControl) cells (Figure 3a,b). Consistently, cell cycle analysis shows that MCF7 cultures
with downregulated MAGI1 have an increased number of cells in S phase and a decreased number in
G0/G1 phase (Figure 3c). Interestingly, the cell population in sub G0/G1 phase, representing cells with
DNA fragmentation, is also reduced in MCF7 cells with downregulated MAGI1, suggesting a possible
effect of MAGI1 downregulation in apoptosis. Annexin-V/DAPI staining analysis confirmed that
MCF7 with downregulated MAGI1 have reduced apoptosis compared to NSControl cells (Figure 3d).
Additionally, in the TCGA dataset, and to a lesser extent in the METABRIC dataset, we observed that
MAGI1 expression is negatively correlated with a proliferative signature (AURKA Proliferation) in
ER+/HER2− BC (See Figure 1b). Consistently, gene ontology analysis in human BC samples revealed
that MAGI1 expression negatively correlates with GO terms involved in the regulation of chromosome
segregation, cell division and cell proliferation (Figure S1b, Table S2).
Next, we tested whether silencing MAGI1 in cells with low expression levels may also affect
proliferation. For this we used the isogenic cell lines 4T1 (ER− expressing low MAGI1 levels) to compare
it to 67NR (ER+ expressing high MAGI1 levels) cells (Figure S2a). Consistent with what we observed
with MCF7 cells, MAGI1 silencing in 67NR cells increased proliferation (Figure S2b). Surprisingly,
however, MAGI1 silencing in 4T1 cells also enhanced proliferation (Figure S2c). These results suggested
that silencing MAGI1 may render ER+ cells (e.g., MCF7 and 67NR) more sensitive to chemotherapy.
To this end, we treated non-silenced and MAGI1-silenced MCF7 and 67NR cells with increasing
concentrations of methotrexate and doxorubicin, two drugs used in BC adjuvant chemotherapy [39],
to determine the IC50 cytotoxic concentrations. Results from this experiment showed that in both cell
lines MAGI1 silencing did not increase sensitivity to the tested drugs (Figure S2d,e).
In complement to these experiments we tested the effect of overexpressing MAGI1b isoform on
the proliferation of the TNBC cell line MDA-MB-231. Overexpression was confirmed by RT-qPCR and
western blotting (Figure S3a,b). MAGI1b overexpression, however, had no effect on MDA-MB-231
proliferation and survival (Figure S3c,d).
As MAGI1 downregulation decreases E2/ER-signaling, it is likely that the increased proliferation
observed in MCF7 may involve an alternative pathway. The PI3K-AKT signaling pathway is activated
in over 60% of ER+ breast cancer and contributes to resistance to ER inhibition and progression [40,41]
and MCF7 cells carry mutations typically found in human luminal breast cancers, including PIK3CA
E545K [42,43]. Interestingly, MAGI1 downregulation increased phosphorylation (S473) of AKT, a direct
target of PI3K, and phosphorylation (S9) of GSKβ3, itself a direct target of AKT [44], and regulator
of the Wnt pathway (Figure 3e). Consistent with GSKβ3 inhibition (phosphorylation) we observed
increased levels of the Wnt target Axin-2 [45] (Figure 3f). In contrast, MAGI1 downregulation did not
alter the phosphorylation of Extracellular Regulated Kinase (ERK) 1/2 (Figure 3g).
We conclude that MAGI1 silencing in MCF7 cells activated the PI3K signaling and Wnt pathways
and promoted MCF7proliferation and survival.
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Figure 3. MAGI1 downregulation increases proliferation, reduces apoptosis and activates PI3K/Wnt
signaling in MCF7 cells. (a) Growth of MCF7 NSControl and MCF7 sh4MAGI1 cells measured as
percentage of cell culture well coverage by the IncuCyte system at the indicated time points (hours) after
plating (n = 18 independent experiments). (b) Cell viability of MCF7 NSControl and MCF7 sh4MAGI1
cells measured by MTT assay and the indicated time points (hours) after plating (n = 6 independent
experiments). (c) Quantification of the percentage of MCF7 cells in the sub G0/G1, G0/G1, S and G2/M
phases of the cell cycle by Edu/DAPI staining (n = 3 independent experiments). (d) Quantification of
the percentage of early, late and total apoptotic MCF7 cells by DAPI/Annexin-V staining and analysis.
The data represents mean values ± S.D. (n = 3 independent experiments). (e) Effect of MAGI1 silencing
(sh4MAGI1) on S473AKT and S9GSKβ3 phosphorylation relative to control (NSControl) in MCF7 cells
revealed by western blotting analysis. (f) Effect of MAGI1 silencing (sh4MAGI1) relative to control
(NSControl) MCF7 cells on AXIN2 expression. The data are shown as percentage of the value of
the housekeeping gene GAPDH, and represent mean values ± S.D. (n = 3 independent experiments,
each analyzed in triplicate). (g) Effect of MAGI1 silencing (sh4MAGI1) on ERK phosphorylation relative
to control (NSControl) in MCF7 cells revealed by western blotting analysis. GAPDH is used as loading
control. Band intensity ratio adjusted to GAPDH is shown next to the blot. Statistical analyses were
performed by unpaired t-test. ns = no statistical difference, * p < 0.05, *** p < 0.005, **** p < 0.001.
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2.4. MAGI1 Downregulation in MCF7 Breast Cancer Cells Reduces Epithelial Differentiation
MAGI1 downregulation in the BC cell line MCF7 leads to loss of E-cadherin localization at cellular
junctions (Figure 4a). In sub-confluent cultures, MCF7 typically forms regular islands of cohesive,
polygonal epithelial cells. MAGI1 downregulation altered this phenotype and induced irregular islands
with elongated or rounded cells and rearranged actin fibers from subcortical to cytoplasmic localization
(Figure 4b). However, MAGI1 downregulation did not induce global reduction of E-cadherin nor
increase of N-cadherin expression (Figure 4c), indicating that MAGI1 downregulation does not cause
epithelial-to-mesenchymal transition but rather a loss of epithelial differentiation traits.
Figure 4. MAGI1 downregulation in MCF7 breast cancer cells reduces epithelial differentiation.
(a) Confocal images of immunofluorescence staining of DAPI (blue), E-cadherin (green) and merged
images in MCF7 NSControl and MCF7 sh4MAGI1 cells (63× objective, 1.5× zoom). (b) Representative
phase-contrast images (20× objective) and confocal images of immunofluorescence staining of phalloidin
(red) and DAPI (blue) (63× objective, 2× zoom) of MCF7 NSControl and MCF7 sh4MAGI1 cells.
Scale bars correspond to 50 µm. (c) Western blot showing MAGI1, E-cadherin, and N-cadherin
protein levels in MCF7 NSControl and MCF7 sh4MAGI1 cells. GAPDH is used as loading control.
Band intensity ratio adjusted to GAPDH is shown next to the blot.
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These observations indicate that reduced MAGI1 expression favors loss of differentiation of BC
cells. In order to corroborate this observation with clinical evidence, we performed HE, ER, and
MAGI1 IHC staining of human breast cancer tissues. We observed that MAGI1 is expressed in well
differentiated ER+ tumors, expressed in lower levels in poorly differentiated ER+ and absent in ER−
BC (Figure 5). From these results we conclude that MAGI1 expression in BC is associated with and
contributes to a differentiated phenotype.
Figure 5. Immunohistochemical analysis of ER and MAGI1 expression in human breast cancers. MAGI1
expression is well expressed in low grade (well differentiated) ER+ tumors, expressed in lower level in
high grade (poorly differentiated) ER+ tumors and absent in ER− tumors. Differentiation (grading) was
determined by HE staining. Scale bar corresponds to 200 µm.
2.5. MAGI1 Downregulation Promotes Metastasis of Disseminated ER+ Cancer Cells
Among the standard clinical and pathological variables, i.e., age (≤50 vs. >50), tumor size (<2 cm vs.
≥2 cm), lymph node status (N0 vs. N+) and histological grade (I–II vs. III), only histological grade shows
a statistically significant differential expression of MAGI1 consistent with the above histopathological
observations (Figure 5). Patients with grade 3 tumors have lower MAGI1 expression compared to
low grade tumors (Figure 6a). This observation is further consistent with the negative correlation
between MAGI1 expression and the histological grade signature (GGI grading) in ER+/HER2− BC
observed at the transcriptomic level in the METABRIC and TCGA datasets (Figure 1b). There was
also a trend (p = 0.062) toward lower expression of MAGI1 in patients with positive lymph node (LN)
status (Figure 6a). These observations suggest that MAGI1 downregulation in ER+/HER2− BC may
promote tumor progression.
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Figure 6. MAGI1 downregulation promotes metastatic progression of ER+ cancers. (a) MAGI1
expression in ER+/HER2− patients from METABRIC microarray analysis by age (≤50 vs. >50),
tumor size (<2 cm vs. ≥2 cm), lymph node status (N0 vs. N+) and histological grade (III vs. I–II).
Statistical analysis was performed by Kruskal–Wallis test (non-parametric one-way ANOVA). (b) MAGI1
silencing enhances growth of primary tumors derived from 67NR cells. Data represent mean values
± S.D (n = 7 mice). (c) MAGI1 silencing enhance lung metastatic nodules number in BALB/c mice
injected via tail vein with 67NR (shMOCK and shMAGI1) cells. Data represent mean values ± S.D.
(n = 5 mice). (d) Quantification of Ki67 staining of lung metastatic nodules of BALB/c mice injected via
tail vein with 67NR (shMOCK and shMAGI1) cells. Ki67 positive cells were counted per high-power
field (63× objective). The data represents mean ± S.D. (n = 18 fields per condition). (e) Quantification
of tumor cells present within the lungs 2 h (2h) or 48 h (48h) after tail vein injection of 67NR (shMOCK
and shMAGI1) cells. (n = 3 mice). Statistical analyses were performed by unpaired t-test. ns = no
statistical difference, * p < 0.05, ** p < 0.01.
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To experimentally assess whether MAGI1 downregulation increased tumor progression, we set up
to perform in vivo tumor growth and metastasis assays. For this we used two sister-cell lines derived
from a mouse adenocarcinoma model in BALB/c [46] with different MAGI1 expression levels (Figure S2a)
and metastatic capacities: 67NR (ER+) being non-metastatic and 4T1 (ER−), highly metastatic [47].
To test whether MAGI1 expression may suppress metastasis, we downmodulated MAGI1 expression
in 67NR cells [48] and up-regulated it in 4T1 cells by shRNA and cDNA overexpression, respectively
(Figure S4a,b). Cells were then orthotopically injected in the fat pad of the 4th mammary gland
and monitored for tumor growth and lung metastatic burden. Downregulation of MAGI1 in 67NR
cells slightly but significantly increased tumor growth (Figure 6b), however we could not detect
neither micro- nor macro-metastasis in the lungs. Given the non-metastatic phenotype of these cells
it is not surprising that downregulation of MAGI1 alone was not sufficient to allow cancer cells to
accomplish the complete metastatic cascade from the primary tumor. Overexpression of MAGI1 in
the 4T1 cell line did not affect tumor growth (Figure S4c), nor it reduced spontaneous lung metastasis
formation (Figure S4d). In order to experimentally test MAGI1 effect on metastatic potential in
67NR cells, we performed an experimental lung metastasis assays, by injecting 67NR cells through
the tail vein. Interestingly, 67NR cells with downregulated MAGI1 generated a higher number of
metastatic nodules in the lungs compared to 67NR shMOCK cells (Figure 6c). Lung metastatic nodules
originated from 67NR with downregulated MAGI1 had a higher fraction of proliferating cells than
controls, as determined by Ki67 IHC staining (Figure S4e and Figure 6d). Consistent with these
observations, 67NR cells with downregulated MAGI1 had a growth advantage in vitro compared to
control cells (Figure S4f).
Seeding and initial survival in the target organ is a rate-limiting step in metastasis formation [49].
To test whether MAGI1 may impinge on seeding and initial survival of cancer cells disseminated
in the lung, we injected fluorescently labeled 67NR cells through the tail vein and sacrificed mice
after 2 h (to assess the fraction of cells retained in the lung) and 48 h (to assess the fractions of cells
initially surviving in the lung). Two hours after injection there was no difference in the number of cells
recovered from the lungs, while at 48 h there were about twice as many viable 67NR cells with silenced
MAGI1 than control cells (Figure 6e).
Taken together, these results indicate that low levels of MAGI1 promote lung metastasis of ER+
67NR cells and this effect is associated with enhanced early survival (i.e., 48 hours’ time point) of
disseminated cancer cells. MAGI1 silenced 67NR cells also form slightly larger primary tumors and
are more proliferative in vitro and in the metastatic nodules.
2.6. Low MAGI1 Expression Predicts Poor Prognosis in ER+ Breast Cancer
To validate whether these experimental in vitro and in vivo observations were of clinical relevance,
we collected correlative evidence in BC patients. To this end, we investigated the prognostic value
of MAGI1 mRNA level in three historical cases series with long-term follow-up and available gene
expression data [50]. In the first set, patients did only receive endocrine treatment (tamoxifen), in the
second, the patients did not receive any type of systemic treatment and in the third, patients were
treated with chemotherapy and endocrine therapy. The detailed clinical-pathological characteristics
of the patients in these three datasets are given in Table S3. The distribution of the standard clinical
variables differs between these three datasets. Since we demonstrated a differential MAGI1 expression
between ER+/HER2−, HER2+, and ER−/HER2− tumors (Figure 1a), we investigated the prognostic
value of MAGI1 expression in each of these subtypes. We found that high MAGI1 expression is
associated with a lower risk of relapse in ER+/HER2− BC treated with tamoxifen at the univariate
(HR 0.58 [0.43–0.80], q = 0.001), and multivariate level (HR 0.50 [0.34–0.73], q = 0.001). The prognostic
value of MAGI1 for disease free survival (DFS) was however absent in the untreated (composed mainly
of low-grade patients without axillary lymph-node involvement) and chemotherapy-treated dataset
(characterized by high-risk features such as lymph node involvement and high grade in more than
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half of the patients) (Figure 7a). In contrast, in the HER2+ and ER−/HER2− subgroups, there was no
association between MAGI1 expression levels and DFS in any of the datasets (Figure 7b,c).
Figure 7. Low MAGI1 expression predicts poor prognosis in ER+ breast cancer. (a–c) Forest plots
showing correlation of MAGI1high, age, tumor size, nodal status and grade with risk of relapse (hazard
ratio, HR) in (a) ER+/HER2−, (b) ER−HER2−, and (c) HER2+ BC patients. Datasets retrieved from
Haibe-Kains et al., 2012 [50]. MAGI1 expression has been considered as a continuous variable. Statistical
analyses were performed with Cox proportional hazards univariate and multivariate models.
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To assess how low MAGI1 expression levels in ER+ BC patients compare to genomic tests in
predicting the risk of recurrence, we used the 21 gene recurrent score (GENE21) [51] as a surrogate for
the OncotypeDX recurrence score [52]. When we added GENE21 to the multivariable Cox regression
model (which includes MAGI1, age, grade and nodal status), both GENE21 and MAGI1 were significant
and anti-correlated in the tamoxifen dataset, meaning that these two variables are independently
associated with DFS (i.e., they provide independent information) in the tamoxifen dataset (Figure S5a).
Next, we investigated the impact of GENE21 on the prognostic effect of MAGI1 in untreated and
chemotherapy-treated ER+/HER2− patients. While increased GENE21 score was associated with
increased risk of relapse in both untreated and chemotherapy-treated patients, the effect of MAGI1 still
remained non-significant in the multivariable models including GENE21 (Figure S5b,c).
Altogether, these results show that MAGI1 provides prognostic information non-redundant
relative to genomic information, in particular for tamoxifen treated patients.
2.7. MAGI1 Expression Negatively Correlates with Inflammation in ER+ Breast Cancer and Is Downregulated
by the Prostaglandin E2 (PGE2)/Cyclooxygenase-2 (COX-2)axis
Considering its clinical relevance, one important emerging question concerns the mechanisms of
downregulation of MAGI1 expression in ER+ BC. We interrogated the TCGA dataset to investigate
whether MAGI1 expression could be influenced by DNA alterations. The results showed that MAGI1
mutations or copy number alterations (CNA) are rare as they are observed in less than 3% of all breast
cancers, and 2% within ER+/HER2− BC (Figure 8a), indicating that DNA alterations are not the major
cause of MAGI1 downregulation.
We have previously shown that in colorectal cancer, MAGI1 expression is negatively or positively
regulated by PGE2 or COX-2 inhibitors (COXIBs), respectively [4]. Taking into consideration the role
of chronic inflammation and PGE2 in cancer development and progression, including in BC [53–56],
we therefore sought to study whether MAGI1 expression was possibly modulated by PGE2 or COXIB
in BC. Indeed, treatment of MCF7 cells with PGE2 and NS-398, a selective COX-2 inhibitor, lead to
downregulation and upregulation of MAGI1 protein levels, respectively (Figure 8b). Downregulation
by PGE2 was further confirmed at mRNA level by RT-PCR (Figure 8c). Importantly, in the METABRIC
and TCGA datasets we observed that in ER+/HER2− BC MAGI1 expression negatively correlates
with immune-inflammatory cellular signatures and with the expression of the monocyte/macrophage
attracting chemokines CCL2 and CCL7 (Figure S6). GO analysis of human data sets revealed that
MAGI1 expression is strongly negatively correlated with biological processes involved in immune and
inflammatory reactions (GO:0002376, q = 3.53x10−77) including leukocyte and lymphocytes activation,
proliferation and cytokine signaling (Figure S1b and Table S2).
These results indicate that MAGI1 expression negatively correlates with immune and inflammatory
gene signatures and processes. Experimentally, the inflammatory mediator PGE2 downregulates
MAGI1 in MCF7 cells, while COX-2 inhibition upregulates it.
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Figure 8. MAGI1 expression negatively correlates with inflammation in ER+ breast cancer and is
modulated by prostaglandin E2 (PGE2)/COX-2axis. (a) Plot representing percentages of BC patients
with MAGI1 mutations and copy number alterations (CNAs) in TCGA datasets. TCGA, n = 1085
(Mutations = 1.198%, Deletions = 1.658%, Amplifications = 0.368%). TCGA ER+HER2−, n = 592
(Mutations = 1.182%, Deletions = 0.675%, Amplifications = 0.168%). (b) Western blot showing MAGI1
protein levels in MCF7 cells treated with 5 µM of PGE2 and 100 µM NS-398 (COX-2 inhibitor) and
corresponding vehicle control (DMSO). GAPDH is used as loading control. Band intensity ratio
adjusted to GAPDH is shown next to the blot. (c) Real time PCR quantification of MAGI1 mRNA in
MCF7 cells treated with either vehicle control (DMSO) or 5 µM PGE2. Data are shown as a percentage of
GAPDH and represent mean values ± SD (n = 3 independent experiments, each analyzed in triplicate).
Statistical analysis was performed by unpaired t-test. ns = no statistical difference, **** p < 0.001.
3. Discussion
In this study, we report three main sets of findings: Firstly, in human BC, MAGI1 expression
is higher in the ER+/HER2− subset, and within this subtype low MAGI1 levels correlate with
a worse prognosis. Secondly, experimental data demonstrate that downregulation of MAGI1 in
ER+/HER2− cancer cells generates a more aggressive cancer cell phenotype. Thirdly, reduced MAGI1
expression in ER+/HER2− cancer correlates with inflammation, based both on human transcriptomic
and experimental data.
We observed that high MAGI1 expression is associated to ER+/HER2− BC subtype while low
MAGI1 expression within this subtype predicts a more aggressive behavior. Among ER+/HER2− BC
patients, high MAGI1 expression positively correlates with ESR1 and the luminal genes GATA3 and
FOXA1. Estradiol treatment of ER+ MCF7 cells upregulates MAGI1 expression. MAGI1 silencing
impairs ESR1 expression and signaling, promotes cell proliferation and reduces apoptosis. Clinically,
loss of ER expression and increased proliferation in luminal ER+ BC patients correlates with a decreased
survival, and predicts resistance to endocrine therapy and benefits from chemotherapy [48,57,58].
MAGI1 silencing in ER+ MCF7 cells increases phosphorylation of AKT (activation) and GSKβ-3
(inactivation) and Axin2 expression demonstrating increased AKT-Wnt signaling. These results suggest
that loss of MAGI1 expression in ER+ BC may promote proliferation and survival though the PI3K-Wnt
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pathway independently from ER signaling. These observations raise the question whether low MAGI1
expression in ER+ BC may correlate with high AKT signaling and resistance to ER antagonists. This is
of potential clinically relevance, as the PIK3CA inhibitor alpelisib in combination with fulvestrant in
progressing ER+HER2− BC with mutated PI3KCA, provides survival advantages [18].
We found that high levels of MAGI1 correlates with a lower risk of relapse in ER+/HER2− patients,
especially in those treated with tamoxifen compared to untreated or chemotherapy-treated patients.
Conversely, ER+ patients treated with chemotherapy have higher grade tumors, more positive LN
and are at higher risk of recurrence [59]. Currently available gene expression signatures, such as
OncotypeDX [52], identify patients that could be safely spared of chemotherapy or patients at high risk
that need chemotherapy, however, they fall short of value in the intermediate score cases [25,26,33,60].
Interestingly, high MAGI1 level and high GENE21 signature [51] were significantly anti-correlated in the
tamoxifen dataset, meaning that these two variables provide independent information relative to DFS
in these patients. The effect of MAGI1 in the multivariable models including the GENE21 signatures
was non-significant in the untreated and chemotherapy treated groups. Altogether, these results
indicate that MAGI1 provides complementary information to currently existing prognostic genomic
tools, in the tamoxifen treated patients. Low MAGI1 expression potentially identifies a subset of ER+
patients treated with tamoxifen with a yet unidentified increased risk of recurrence.
We further observed that low MAGI1 expression is associated with higher histological grade,
increased cell proliferation and reduced epithelial differentiation suggesting that MAGI1 expression is
downregulated during tumor progression, consistent with previous reports [4–6]. Higher histological
grade is positively associated with increased risk of metastatic progression [61]. Consistently, in the
67NR ER+ murine BC model, MAGI1 downregulation increases lung metastasis formation possibly
promoting tumor cell extravasation, initial seeding and/or early survival in the lung preceding
metastatic niche formation [62–64]. In contrast, MAGI1 expression levels do not impact TNBC patient
prognosis, a patient subgroup characterized by high-grade tumors, and experimental upregulation of
MAGI1 in TNBC-like 4T1 tumor cells does not reduce their metastasis capacity.
A main arising question concerns the mechanism of MAGI1 downregulation in ER+/HER2− BC
cells. MAGI1 gene mutations or copy number alterations appear not to be involved. Strikingly, MAGI1
expression negatively correlates with inflammatory/immune signatures in patients, and PGE2 or COXIB
treatment of ER+ MCF7 cells reduces or enhances MAGI1 expression, respectively. We have previously
reported similar observations in colorectal cancer cells [4]. Considering that chronic inflammation is
associated with an increased risk of cancer incidence and progression [65], this is a highly clinically
relevant observation. COX-2, the rate-limiting enzyme in PGE2 synthesis, is overexpressed in several
cancers including BC [53,57]. PGE2 stimulates tumor cell proliferation, invasion, and angiogenesis,
inhibits tumor cell apoptosis, and promotes immunosuppression [54,66,67]. Preclinical and clinical
studies showed that nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects on
several cancers including BC [68–70], and exert anti-tumor activities, and in particular ketorolac when
administrated in the peri-operative setting [65,71]. However, their routine use as adjuvant treatment in
BC is still inconsistent and not yet recommended [72–79]. Of interest, mounting evidence indicate that
inflammation may promote acquired endocrine resistance and more aggressive progression or ER+
BC [80–83]. Whether MAGI1 is part of this mechanism, and whether this protein is possibly regulated
by other tumor-promoting mediators of inflammation (e.g., TNF, IL6) is an attractive hypothesis that
deserves further investigations.
4. Materials and Methods
4.1. Cell Lines
The human MCF7 and MDA-MB-231 BC cell lines were obtained from the American Type Culture
Collection (ATCC, Manassas, WV, USA) and the murine BC cell lines 4T1, 67NR were obtained from Dr.
Fred Miller (Michigan Cancer Foundation, Detroit, MI, USA). Cells were cultured in Dulbecco’s modified
Cancers 2020, 12, 223 16 of 23
Eagle’s medium (DMEM) supplemented with 10% FBS, 1% penicillin/streptomycin, and maintained in
a humidified incubator at 37 ◦C and 5% CO2.
4.2. Cell Treatments
For PGE2 or COX-2 inhibitor treatment, MCF7 cells were treated for 48 h with 5 µM PGE2 (Enzo
Life Sciences, Lausen, Switzerland), or for 72 h with 100 µM NS-298 (inhibitor of COX-2) (Enzo Life
Sciences). DMSO was used as a control vehicle for both treatments. For 17-β-estradiol treatment, MCF7
cells were serum starved for 48 h in phenol-red-free DMEM/F-12 media (SFM). Cells were treated for 6
h with either 10−6 M 17-β-estradiol (Sigma-Aldrich, St. Louis, MO, USA) or a vehicle control (ethanol,
0.1%). For ER inhibition experiments, 10 µM 4-Hydroxi-Tamoxifen (Tocris Bioscience, Cat. No. 3412,
Bristol, UK) or 0.5 µM ICI 182,780 (Tocris Bioscience, Cat. No. 1047) were added to cells 1 h before
10−6 M 17-β-estradiol and further cultured for another 6 h as above. For the control condition cells were
treated with ethanol 0.1%. After treatments, either protein or total RNA was extracted and western
blot or quantitative real-time PCR was performed.
4.3. Animal Procedures Authorization
All animal procedures were performed in accordance with the Swiss legislations on animal
experimentation and approved by the Cantonal Veterinary Service of the Cantons Fribourg (2014_58_FR
and 2017_34FR).
4.4. Spontaneous Tumor Models
MMTV-PyMT (FVB/N) mice were bred and housed in ventilated cages in the OHB mouse
husbandry of the University of Fribourg. Spontaneously-derived PyMT-MMTV tumors [84]
were extracted from 4-month old mice and tumor samples were stored and pulverized in liquid
nitrogen. RNA was extracted as described in Supplementary Materials and methods.
4.5. Orthotopic Tumor Models
4T1 cells (2.5 × 105 cells in 100 µl PBS) either transduced with the control vector (psD44 MOCK) or
with a MAGI1 expressing vector (psD44 MAGI1OE), were injected in the mammary fat pad of the fourth
inguinal mammary gland of 7-week-old female BALB/c mice (Envigo, Huntingdon, UK). 67NR cells
(4 × 105 cells in 50 µl PBS) either transduced with a control vector (shMOCK or shControl) or with
MAGI1 short hairpin RNA expressing vector (shMAGI1), were injected as above in 6-week-old female
NSG mice (Animal facility University of Lausanne, Lausanne, Switzerland). To monitor tumor growth,
tumor size was measured at regular intervals and tumor volume was calculated with the following
equation: Tumor volume = (length × width2)/2. At the end of the experiment mice were sacrificed and
lungs were resected. Lung macro-metastases at the surface were counted with a stereomicroscope,
thereafter lungs were fixed in 4% PFA overnight and then prepared for paraffin-embedding.
4.6. Experimental Lung Metastasis Model
67NR cells (25 × 104 cells in 100 µL PBS) either transduced with a control vector (shMOCK)
or with MAGI1 short hairpin RNA expressing vector (shMAGI1), were injected via the tail vein
into 7-week-old BALB/c female mice (Envigo, Huntingdon, UK). 21 days post-injection mice were
sacrificed and lungs were resected for metastasis measurements. Lung macro-metastases at the surface
were counted with a stereomicroscope and lungs were incubated overnight in 4% PFA and then
paraffin-embedded for sectioning and HE and immunohistochemistry staining. For monitoring the
in vivo fate of injected cancer cells, 67NR cells (shMOCK and shMAGI1) were stained with 5 µM
green fluorescent dye Cell-Tracer CFSE (Thermo Fisher Scientific, Waltham, MA, USA) following the
manufacturer’s instructions. 105 cells were injected via tail vein into 7-week-old BALB/c female mice
(Envigo, Huntingdon, UK). Mice were divided into two groups: the first group was sacrificed after 2 h
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(to quantify tumor cells sequestered in the lungs) and the second group was sacrificed 48 h post-injection
(to quantify tumor cell extravasation and early survival into the lungs). When mice were sacrificed,
lungs were resected for flow cytometry analysis. Lung samples were disaggregated with a digestion
solution composed by 0.4 U/mL Liberase TH Research grade (Roche, Basel, Switzerland) and 25 µg/mL
DNase I (DN25) (Sigma-Aldrich, St. Louis, MO, USA), for 1 h at 37 ◦C. Disaggregated lungs were
washed with PBS-EDTA (2 mM) and PBS, and filtered with 70-µm mesh (Biologix, Shandong, China).
Finally, red blood cells were lysed with ACK lysis buffer (Thermo Fisher Scientific, Waltham, MA,
USA). Samples were filtered again with a 70-µm mesh and analyzed by flow cytometry with MACS
Quant Analyzer 10 (Miltenyi Biotec, Bergisch Gladbach, Germany). Data analysis was performed
with FlowJo.
4.7. Cytoimmunofluorescence Staining
Cells were plated in sub-confluent conditions on glass cover-slips placed in 12 well plates and
cultured for 24–48 h in complete media or phenol-red serum-free DMEM/F-12 (SFM). Thereafter,
cells were fixed with 4% PFA for 15 min at 4 ◦C and washed with PBS. To block unspecific binding
of the antibodies, cells were incubated with 5% Donkey serum (Sigma-Aldrich) for 1 h at room
temperature. Then, samples were incubated with primary antibodies for 1 h at room temperature.
After four washings with 1x PBS, samples were incubated with secondary antibodies conjugated to
Alexa fluor-488,546,568 or 647 as necessary for 1 h at room temperature in a humid-chamber protected
from light. Cell nuclei were counterstained and mounted in ProLongTM Gold antifade reagent with
DAPI (Thermo Fisher Scientific). Images were acquired with a Leica TCS SP5 inverted confocal laser
scanning microscope using a 40× or 63× objective and with a pinhole of 1 AU to minimize z-section.
4.8. Tissue Staining
Histopathological and immunohistochemical analyses of mouse tissues. Standard hematoxylin–eosin
(HE) and Ki67 staining procedures were performed on paraffin-embedded tissues. Tissue sections
were digitalized by the slide scanner Hamamatsu Nanozoomer (Hamamatsu, Japan). Proliferation
in Ki67 stained slides were assessed by counting Ki67+ breast cancer cells per field in scanned slides
(63× zoom in Nanozoomer).
Histopathological and immunohistochemical analyses of human tumors. Stained tumors were part
of a Tissue Macro Array (TMA) kindly provided by the Tissuebank Bern (TBB). TMAs were cut
at 3µm sections and mounted onto glass slides, dried and baked at 60 ◦C for 30 min prior to use.
HE staining was performed following standard procedures. Immunohistochemistry was performed by
automated staining using Bond RX (Leica Biosystems, Wetzlar, Germany) immunostainer. All slides
were dewaxed in Bond dewax solution (Leica Biosystems). Heat-induced epitope retrieval was
performed at pH 9 in Tris buffer based (Leica Biosystems) for 30 min at 95◦. MAGI1 rabbit polyclonal
antibody (Sigma Aldrich, Munich, Germany) was incubated for 30 min at 1:50 dilution. Then samples
were incubated with HRP (Horseradish Peroxidase)-polymer for 15 min and subsequent visualized
using 3,3-Diaminobenzidine (DAB) as brown chromogen (Leica Biosystems) for 10 min. Finally, the
samples were counterstained with Haematoxylin, dehydrated and mounted with PERTEX®(Histolab,
Gothenburg, Sweden). Slides were scanned and photographed using Pannoramic 250 scanner and
Case Viewer (3DHistech, Budapest, Hungary). Tissues were used upon approval and in accordance
with ethical institutional rules (ethics approval number: KEK 200/2014).
4.9. Bioinformatic Analyses—Gene Expression and Survival Analyses
The METABRIC [34] and TCGA dataset [35] including clinical data and normalized gene expression,
was retrieved through cBioportal on the 08/04/19 [37]. Subtypes were assessed according to the
ER immunohistochemistry and HER2 immunohistochemistry or FISH status. Tamoxifen-treated,
systemically untreated node negative patients, and chemotherapy treated patient were retrieved from
the dataset in [50]. Gene expression signatures were retrieved from the literature (ESR1_signature,
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AURKA, PLAU, STAT1 [85]; GGI [86]; SDPP [87]; Immune_Perez [88]; IRM [89]; immune cell
signatures [90]; GENE21 [91] and computed as described in [92]. Wilcoxon and Kruskal–Wallis tests
were performed to compare continuous to categorical variables of 2 or more categories, respectively.
Correlations were assessed using Spearman coefficients. In the heatmap only significant correlations are
colored: Red, anti-correlated; blue correlated. Survival analysis were performed with Cox proportional
hazards univariate models and multivariable models (corrected for age (>50 vs. ≤50), tumor size
(≥2 vs. <2), nodal status (pos vs. neg), grade (III vs. I–II)), all additionally corrected for dataset of
origin. p-values were two-sided and statistical significance considered for p < 0.05. All analyses were
performed using R 3.5.2.
4.10. Bioinformatic Analyses—Gene Onthology Analyses
Genes were considered associated with MAGI1 expression in TCGA when the spearman coefficients
were q-value < = 0.01 according to FDR. Positively and negatively associated genes were analyzed
independently. Genes were first analyzed with PANTHER [93] for overrepresentation test in Homo
sapiens within the complete GO biological process. Significant GO terms (FDR < 0.05) were summarized
using REVIGO [94] with default parameters.
4.11. Statistical Analysis (Except Bioinformatics Analysis)
Normal distribution of samples was assessed by Shapiro-Wilk test. Data from in vitro and in vivo
experiments were analyzed by Student’s t test or Mann–Whitney test when applicable. Primary
tumor growth was analyzed by a two-way ANOVA. Results were considered significant with at least
p < 0.05 (*), p < 0.01 (**), p < 0.005 (***), and p < 0.001 (****). Results are expressed as mean ± SD unless
otherwise indicated.
5. Conclusions
In conclusion, we have identified previously unrecognized features and functions of MAGI1 in
ER+/HER2− BC: MAGI1 is highly expressed and has tumor suppressor activity in ER+/HER2− BC
subset. MAGI1 loss within this subset correlates with a more aggressive phenotype and identifies
patients at higher risk of recurrence. MAGI1 loss positively correlates with inflammation in patients
and COX-2 inhibition upregulates its expression. The present observations reinforce the status of
MAGI1 as a potential tumor suppressor downregulated during inflammation and cancer progression
and upregulated by COXIBs. Whether and how these observations may translate into improved
therapy will require additional studies.
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